Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.

Zobair M YounossiArian AfendyMaria StepanovaAndrei RacilaFatema NaderRachel GomelRicky SaferWilliam R LenderkingAnne SkalickyLeah KleinmanRobert P MyersG Mani SubramanianJohn G McHutchisonCynthia LevyChristopher L BowlusKris KowdleyAndrew J Muir

Published in: Hepatology (Baltimore, Md.) (2018)

PSC PRO is a self-administered disease-specific instrument developed according to U.S. Food and Drug Administration guidelines. This preliminary validation study suggests good psychometric properties. Further validation of the instrument in a larger and more diverse sample of PSC patients is needed. (Hepatology 2018;68:155-165).

Keyphrases

patient reported outcomes
psychometric properties
drug administration
anti inflammatory
newly diagnosed
end stage renal disease
ejection fraction
prognostic factors
peritoneal dialysis
risk assessment